Hanna Dahlstrand

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer.

Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer.

Journal: Immuno-oncology technology
Published: March 11, 2026

Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohort.

Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohort.

Journal: Translational oncology
Published: May 24, 2025

High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.

High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.

Journal: Gynecologic oncology
Published: August 13, 2024

Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.

Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.

Journal: Cancer research communications
Published: May 24, 2024

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer.

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer.

Journal: Cancer causes & control : CCC
Published: December 01, 2023

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)
Published: September 26, 2023

Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.

Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.

Journal: Seminars in cancer biology
Published: December 15, 2021

The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types.

The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types.

Journal: EBioMedicine
Published: October 13, 2020

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

Journal: Upsala journal of medical sciences
Published: October 12, 2020

Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor.

Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor.

Journal: Advances in therapy
Published: August 13, 2020

High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.

High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.

Journal: Gynecologic oncology
Published: May 11, 2020

Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers.

Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers.

Journal: PloS one
Published: March 02, 2020
Showing 1-12 of 22

Last Updated: 09/26/2026